Sun Pharma announces FDA tentative approval for generic Cymbalta

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Your Guide for Turning Grief into Action

Grief is a deeply personal and often overwhelming experience....

Why Use a Provider Network for Pain Management After an Accident?

Pain after an accident can be overwhelming and can...

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride delayed-release capsules, 20 mg (base), 30 mg (base), and 60 mg (base) are indicated in the treatment of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD) and Diabetic Peripheral Neuropathic Pain

Latest stories

Related stories

Your Guide for Turning Grief into Action

Grief is a deeply personal and often overwhelming experience....

Why Use a Provider Network for Pain Management After an Accident?

Pain after an accident can be overwhelming and can...

How Early Regulatory Planning Saves Time and Money in Product Development

Incorporating early regulatory planning in product development can significantly...

America’s AI Action Plan Boosts Pharmaceutical Innovation

Accelerating Pharmaceutical and Biopharmaceutical Innovation through America’s AI Action...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back